Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1991-09

AUTHORS

T Visakorpi, O-P Kallioniemi, IYI Paronen, JJ Isola, AI Heikkinen, TA Koivula

ABSTRACT

We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high SPF (greater than 4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall (P = 0.004 and P less than 0.0001) as well as prostate cancer survival (P = 0.002 and P less than 0.0001). Ten-year overall survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free survival in patients treated hormonally. In conclusion, detection of high SPF in prostate cancer may indicate lack of hormonal responsiveness and poor prognosis. More... »

PAGES

578-582

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1991.353

DOI

http://dx.doi.org/10.1038/bjc.1991.353

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032654845

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1911201


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aneuploidy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diploidy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estramustine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogens", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flow Cytometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ploidies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "S Phase", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Chemistry, Tampere University Hospital, Finland", 
          "id": "http://www.grid.ac/institutes/grid.412330.7", 
          "name": [
            "Department of Clinical Chemistry, Tampere University Hospital, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Visakorpi", 
        "givenName": "T", 
        "id": "sg:person.0724222311.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724222311.57"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Kallioniemi", 
        "givenName": "O-P", 
        "id": "sg:person.01055637437.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055637437.35"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Paronen", 
        "givenName": "IYI", 
        "type": "Person"
      }, 
      {
        "familyName": "Isola", 
        "givenName": "JJ", 
        "id": "sg:person.0773456240.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773456240.07"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Heikkinen", 
        "givenName": "AI", 
        "id": "sg:person.01003770472.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003770472.51"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Koivula", 
        "givenName": "TA", 
        "id": "sg:person.01103006210.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103006210.08"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1991-09", 
    "datePublishedReg": "1991-09-01", 
    "description": "We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high SPF (greater than 4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall (P = 0.004 and P less than 0.0001) as well as prostate cancer survival (P = 0.002 and P less than 0.0001). Ten-year overall survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free survival in patients treated hormonally. In conclusion, detection of high SPF in prostate cancer may indicate lack of hormonal responsiveness and poor prognosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1991.353", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "64"
      }
    ], 
    "keywords": [
      "prostatic carcinoma", 
      "tumor grade", 
      "high SPF", 
      "Ten-year overall survival rates", 
      "prostate cancer-specific survival rate", 
      "cancer-specific survival rates", 
      "survival rate", 
      "DNA ploidy", 
      "progression free survival", 
      "overall survival rate", 
      "primary prostatic carcinoma", 
      "prostate cancer survival", 
      "high tumor grade", 
      "DNA flow cytometry", 
      "objective response", 
      "free survival", 
      "distant metastasis", 
      "median SPF", 
      "poor prognosis", 
      "lower SPF values", 
      "endocrine responsiveness", 
      "cancer survival", 
      "prostate cancer", 
      "DNA aneuploidy", 
      "hormonal responsiveness", 
      "flow cytometry", 
      "cytometric analysis", 
      "phase fraction", 
      "prognosis", 
      "carcinoma", 
      "therapy", 
      "SPF", 
      "SPF values", 
      "survival", 
      "responsiveness", 
      "best predictor", 
      "ploidy", 
      "grade", 
      "patients", 
      "metastasis", 
      "tumors", 
      "prostate", 
      "cancer", 
      "response", 
      "cytometry", 
      "predictors", 
      "aneuploidy", 
      "rate", 
      "conclusion", 
      "stage", 
      "cases", 
      "lack", 
      "fraction", 
      "presence", 
      "values", 
      "large size", 
      "higher values", 
      "detection", 
      "implications", 
      "analysis", 
      "size", 
      "paraffin-embedded primary prostatic carcinomas", 
      "corresponding prostate cancer-specific survival rates"
    ], 
    "name": "Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy", 
    "pagination": "578-582", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032654845"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1991.353"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1911201"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1991.353", 
      "https://app.dimensions.ai/details/publication/pub.1032654845"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_240.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1991.353"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.353'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.353'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.353'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.353'


 

This table displays all metadata directly associated to this object as RDF triples.

218 TRIPLES      21 PREDICATES      106 URIs      98 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1991.353 schema:about N05f2fe6ed18a4075b028df1b369f089e
2 N0c8f4701242a4260b472bf8737654d5c
3 N2804fcf1d6b6464db754bad7d0bdd1e1
4 N42e4ada3bbb0492b887f16da64bbed5f
5 N4bcadcb7c23c4bcba8556969e5197275
6 N769518904e8b4f62ac0e732f0291ffb3
7 N7c2f88196af5499f913750a60bb1e829
8 N81be4198fd4e430191d5423db48d5253
9 N927ceceb362b4699acc677a2c05b4694
10 Na77d0ee5c35e4415a12c518a00bf7232
11 Nba472e237888411fbc93b15cbb275f21
12 Nbb28116b7e2c4968a1f7e651bfe408b6
13 Nc107b7b8e54846fbad857b28496cfdca
14 Nc7484ec4592e471baea718988671ab4a
15 Nef9a7a2f71c84d9486f63c338b5a71d5
16 Nf62e30c03ca449d190b86e4b42c2ad22
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N30934425389f412eb65a041405bd27a0
20 schema:datePublished 1991-09
21 schema:datePublishedReg 1991-09-01
22 schema:description We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high SPF (greater than 4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall (P = 0.004 and P less than 0.0001) as well as prostate cancer survival (P = 0.002 and P less than 0.0001). Ten-year overall survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free survival in patients treated hormonally. In conclusion, detection of high SPF in prostate cancer may indicate lack of hormonal responsiveness and poor prognosis.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N799ae05914254dcc9c1698b7e89735a7
27 Nce0537596e154e0ba97f7fca59ae59d2
28 sg:journal.1017082
29 schema:keywords DNA aneuploidy
30 DNA flow cytometry
31 DNA ploidy
32 SPF
33 SPF values
34 Ten-year overall survival rates
35 analysis
36 aneuploidy
37 best predictor
38 cancer
39 cancer survival
40 cancer-specific survival rates
41 carcinoma
42 cases
43 conclusion
44 corresponding prostate cancer-specific survival rates
45 cytometric analysis
46 cytometry
47 detection
48 distant metastasis
49 endocrine responsiveness
50 flow cytometry
51 fraction
52 free survival
53 grade
54 high SPF
55 high tumor grade
56 higher values
57 hormonal responsiveness
58 implications
59 lack
60 large size
61 lower SPF values
62 median SPF
63 metastasis
64 objective response
65 overall survival rate
66 paraffin-embedded primary prostatic carcinomas
67 patients
68 phase fraction
69 ploidy
70 poor prognosis
71 predictors
72 presence
73 primary prostatic carcinoma
74 prognosis
75 progression free survival
76 prostate
77 prostate cancer
78 prostate cancer survival
79 prostate cancer-specific survival rate
80 prostatic carcinoma
81 rate
82 response
83 responsiveness
84 size
85 stage
86 survival
87 survival rate
88 therapy
89 tumor grade
90 tumors
91 values
92 schema:name Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy
93 schema:pagination 578-582
94 schema:productId N14c6bcd496d74210ad9688069946a27a
95 N6b04219f346f4a8383cd63638898c0f0
96 N8f64a96e4db2433991f09ef795a8c062
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032654845
98 https://doi.org/10.1038/bjc.1991.353
99 schema:sdDatePublished 2021-12-01T19:08
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N71a7d709b608475cbabbe47f2c236cb6
102 schema:url https://doi.org/10.1038/bjc.1991.353
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N05f2fe6ed18a4075b028df1b369f089e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name S Phase
108 rdf:type schema:DefinedTerm
109 N08893485e3f746d689b6007d9ce9349a rdf:first sg:person.01055637437.35
110 rdf:rest N64d8c77435674743aad519037350f05e
111 N0c8f4701242a4260b472bf8737654d5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Prostatic Neoplasms
113 rdf:type schema:DefinedTerm
114 N14c6bcd496d74210ad9688069946a27a schema:name doi
115 schema:value 10.1038/bjc.1991.353
116 rdf:type schema:PropertyValue
117 N2804fcf1d6b6464db754bad7d0bdd1e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Prognosis
119 rdf:type schema:DefinedTerm
120 N300bf764390640f5a6f2e6e0ef2e57bb schema:familyName Paronen
121 schema:givenName IYI
122 rdf:type schema:Person
123 N30934425389f412eb65a041405bd27a0 rdf:first sg:person.0724222311.57
124 rdf:rest N08893485e3f746d689b6007d9ce9349a
125 N42e4ada3bbb0492b887f16da64bbed5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Prostatectomy
127 rdf:type schema:DefinedTerm
128 N4bcadcb7c23c4bcba8556969e5197275 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Estramustine
130 rdf:type schema:DefinedTerm
131 N64d8c77435674743aad519037350f05e rdf:first N300bf764390640f5a6f2e6e0ef2e57bb
132 rdf:rest Nf29975be27dd4abcae2d30395b49907c
133 N6b04219f346f4a8383cd63638898c0f0 schema:name pubmed_id
134 schema:value 1911201
135 rdf:type schema:PropertyValue
136 N71a7d709b608475cbabbe47f2c236cb6 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 N769518904e8b4f62ac0e732f0291ffb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Diploidy
140 rdf:type schema:DefinedTerm
141 N799ae05914254dcc9c1698b7e89735a7 schema:issueNumber 3
142 rdf:type schema:PublicationIssue
143 N7a3c9b59166a4337a8d09cb726c80a33 rdf:first sg:person.01103006210.08
144 rdf:rest rdf:nil
145 N7c2f88196af5499f913750a60bb1e829 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Follow-Up Studies
147 rdf:type schema:DefinedTerm
148 N81be4198fd4e430191d5423db48d5253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name DNA, Neoplasm
150 rdf:type schema:DefinedTerm
151 N8f64a96e4db2433991f09ef795a8c062 schema:name dimensions_id
152 schema:value pub.1032654845
153 rdf:type schema:PropertyValue
154 N927ceceb362b4699acc677a2c05b4694 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Middle Aged
156 rdf:type schema:DefinedTerm
157 Na653f61bbc8348a994292d14e5a04e90 rdf:first sg:person.01003770472.51
158 rdf:rest N7a3c9b59166a4337a8d09cb726c80a33
159 Na77d0ee5c35e4415a12c518a00bf7232 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Aneuploidy
161 rdf:type schema:DefinedTerm
162 Nba472e237888411fbc93b15cbb275f21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Male
164 rdf:type schema:DefinedTerm
165 Nbb28116b7e2c4968a1f7e651bfe408b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Flow Cytometry
167 rdf:type schema:DefinedTerm
168 Nc107b7b8e54846fbad857b28496cfdca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Aged
170 rdf:type schema:DefinedTerm
171 Nc7484ec4592e471baea718988671ab4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Humans
173 rdf:type schema:DefinedTerm
174 Nce0537596e154e0ba97f7fca59ae59d2 schema:volumeNumber 64
175 rdf:type schema:PublicationVolume
176 Nef9a7a2f71c84d9486f63c338b5a71d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Estrogens
178 rdf:type schema:DefinedTerm
179 Nf29975be27dd4abcae2d30395b49907c rdf:first sg:person.0773456240.07
180 rdf:rest Na653f61bbc8348a994292d14e5a04e90
181 Nf62e30c03ca449d190b86e4b42c2ad22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Ploidies
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1017082 schema:issn 0007-0920
191 1532-1827
192 schema:name British Journal of Cancer
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01003770472.51 schema:familyName Heikkinen
196 schema:givenName AI
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003770472.51
198 rdf:type schema:Person
199 sg:person.01055637437.35 schema:familyName Kallioniemi
200 schema:givenName O-P
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055637437.35
202 rdf:type schema:Person
203 sg:person.01103006210.08 schema:familyName Koivula
204 schema:givenName TA
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103006210.08
206 rdf:type schema:Person
207 sg:person.0724222311.57 schema:affiliation grid-institutes:grid.412330.7
208 schema:familyName Visakorpi
209 schema:givenName T
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724222311.57
211 rdf:type schema:Person
212 sg:person.0773456240.07 schema:familyName Isola
213 schema:givenName JJ
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773456240.07
215 rdf:type schema:Person
216 grid-institutes:grid.412330.7 schema:alternateName Department of Clinical Chemistry, Tampere University Hospital, Finland
217 schema:name Department of Clinical Chemistry, Tampere University Hospital, Finland
218 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...